Oncolytic Vaccinia Virus in Lung Cancer Vaccines
- 문서 유형
- 연구출판물 · 리뷰논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- VACCINES10(2) · 2022
- 피인용
- Web of Science 28Scopus 31
- FWCI (Scopus)
- 0.95
- JCR IF
- JCR 2021 4.961
- ISSN
- 2076-393X
저자
초록
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.Therapeutic cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adverse effects by specifically targeting tu-mor-associated antigens. Oncolytic virus, especially vaccinia virus (VV) is a promising cancer treatment option for effective cancer immunotherapy and thus can also be utilized in cancer vac-cines. Non-small cell lung cancer (NSCLC) is likely to respond to immunotherapy, such as immune checkpoint inhibitors or cancer vaccines, since it has a high tumor mutational burden. In this re-view, we will summarize recent applications of VV in lung cancer treatment and discuss the potential and direction of VV-based therapeutic vaccines.
키워드
Cancer vaccineImmunotherapyNon-small cell lung cancerOncolytic virusPersonalized vaccinationVaccinia virusSWITCH MAINTENANCE THERAPYGROWTH-FACTOR VACCINETUMOR CELL VACCINEPHASE-II TRIALBELAGENPUMATUCEL-L1ST-LINE CHEMOTHERAPYCLINICAL-TRIALDOUBLE-BLINDCIMAVAX-EGFIMMUNOTHERAPY
식별자
- Scopus EID
- 2-s2.0-85124016869
- WoS UID
- 000762040200001



로그인
연구물 목록으로